Cantargia publishes interim report for third quarter 2019
Cantargia AB’s (”Cantargia”) interim report for the period January until September 2019 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the third quarter · In July, full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial, was announced. · Cantargia and BioWa extended the ongoing collaboration around the POTELLIGENT® Technology. · In August positive preclinical data on CAN04 in bladder cancer were announced. · Cantargia requested a pre-IND meeting regarding CAN04 with the US FDA.